证券代码：301188 证券简称：力诺特玻 山东力诺特种玻璃股份有限公司 投资者关系活动记录表 编号：2022-001 | --- | --- | --- | --- | --- | |-----------------------------|-----------------------------------------------------------------------------------|------------------------------------------------|-------|---------| | 投资者关系活动 | √特定对象调研 □分析师会议 \n□媒体采访 □业绩说明会 | | | | | 类别 | □新闻发布会 □路演活动 | | | | | | □现场参观 □其他 | | | | | 参与单位名称 及人员姓名 | 东北证券 - 陈渊文，唐凯 光大证券 - 冯孟乾 天风证券 - 范张翔，王月 广发证券 - 苗蒙 | | | | | 时间 | 2022 年 1 月 10 日 | 14:00 | | | | 地点 | 力诺特玻 3 号会议室 | | | | ...

证券代码：301188 证券简称：力诺特玻 山东力诺特种玻璃股份有限公司 投资者关系活动记录表 编号：2022-003 | --- | --- | --- | |-----------------------------|--------------------------------|------------------------------------------------------------------------------------------------------------------------------------------| | | | 特定对象调研 □分析师会议 | | | □媒体采访 | □业绩说明会 | | 投资者关系活动 类别 | □新闻发布会 | 路演活动 | | | □现场参观 | 其他 | | 参与单位名称 及人员姓名 | 构投资者 | 中海基金、永赢基金、中邮基金、长信基金等 | | 时间 | 2022 年 2 月 16 日 | 9:30 | | 地点 | 公司会议室 | | | 上市公司接待人员 姓名 | | 副总经理、财务总监、董事会秘书：丁亮 副总经理 ...

Group 1: Company Projects and Developments - The company has successfully launched several new projects, including a fully electric intelligent pharmaceutical glass production line, which began operations in July 2022, aimed at reducing production costs for low borosilicate glass [1][3]. - The molded bottle project was initiated in August 2022 and has received regulatory approval as of October 18, 2022, with production currently underway [3][4]. - The mid-borosilicate glass tube project was successfully launched in October 2022 and is progressing as planned [3][4]. Group 2: Financial Performance and Market Strategy - The company aims to enhance shareholder value by expanding its capacity in the molded bottle sector through the construction of a "Phase III Project" [3][5]. - The company has adopted a sales-driven production model, aligning production with market demand and customer orders [5][6]. - Despite facing challenges due to external uncertainties, the company is committed to achieving its operational goals and improving cost efficiency [6]. Group 3: Investor Relations and Communication - The company emphasizes the importance of communication with investors and plans to enhance its information disclosure quality [4][5]. - There has been no notification from shareholders regarding any plans to reduce their holdings following the lifting of restrictions on November 11, 2022 [3][4]. - The company is actively monitoring its stock price trends and is focused on maintaining investor confidence and market recognition of its intrinsic value [4][5].

证券代码：301188 证券简称：力诺特玻 山东力诺特种玻璃股份有限公司 投资者关系活动记录表 编号：2022-006 | --- | --- | --- | |----------------------|------------------------|--------------------------------------------------------------------------------------------------------------------------| | | | | | | 特定对象调研 | ☐分析师会议 | | | ☐媒体采访 | ☐ 业绩说明会 | | 投资者关系活动类别 | ☐ 新闻发布会 | ☐ 路演活动 | | | 现场参观 | | | | ☐ | 其他（请文字说明其他活动内容） | | 形式 | 现场 ☐网上 | ☐ 电话会议 | | 参与单位名称及人员 | 安资本等 17 | 中信证券、东兴证券、中信建投、西南证券、东海 证券、天风证券、东方证券、宏道投资、银河证券、益 家机构研究员、分析师等人员 | | 姓名 | | | | 时间 | 2022 ...

证券代码：301188 证券简称：力诺特玻 公告编号：2022-072 山东力诺特种玻璃股份有限公司 关于参加山东辖区上市公司 2022 年度投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流工作，构建和谐投资者关系，切实提高上 市公司透明度和治理水平，山东力诺特种玻璃股份有限公司（以下简称"公司"） 将参加中国证券监督管理委员会山东监管局、山东上市公司协会联合举办并由深 圳市全景网络有限公司承办的"山东辖区上市公司2022年度投资者网上集体接待 日"活动，现将有关事项公告如下： 本次投资者集体接待活动将采用网络远程的方式举行，活动时间：2022 年 11 月 16 日（星期三）下午 14:00-16:00；活动网址：全景网"投资者关系互动平 台"（http://ir.p5w.net/），投资者可登录活动网址参与本次活动，届时公司董事 长孙庆法先生，副董事长、总经理杨中辰先生，副总经理、董事会秘书、财务总 监丁亮先生将通过网络在线交流形式与投资者就公司治理、经营状况、发展战略、 三季度报告等投资者关 ...

Financial Performance - Revenue for Q3 2022 was CNY 193,743,230.20, a decrease of 11.59% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2022 was CNY 24,879,405.46, down 27.79% year-on-year[5] - Basic earnings per share for Q3 2022 was CNY 0.10, a decline of 50.00% compared to the previous year[5] - The total operating revenue for the third quarter of 2022 was CNY 569,199,802.61, a decrease of approximately 11.14% compared to CNY 640,711,860.62 in the same period last year[21] - The net profit for Q3 2022 was CNY 86,618,449.91, a decrease of 9.4% compared to CNY 95,988,999.06 in Q3 2021[22] - Operating profit for Q3 2022 was CNY 98,591,776.50, down from CNY 109,586,612.53 in the same period last year, reflecting a decline of approximately 10.1%[22] - The total comprehensive income for Q3 2022 was CNY 86,618,449.91, a decrease from CNY 95,988,999.06 in Q3 2021[23] Cash Flow and Assets - Cash flow from operating activities for the year-to-date was CNY 1,846,965.87, a significant drop of 96.72%[10] - The company's cash and cash equivalents decreased to CNY 372,692,317.11 from CNY 710,788,542.58 at the beginning of the year, indicating a decline of approximately 47.5%[17] - Cash and cash equivalents at the end of Q3 2022 were CNY 327,096,987.49, down from CNY 68,122,238.49 at the end of Q3 2021[27] - The net cash flow from investing activities was CNY -311,278,194.35, a 743.21% increase in outflow compared to the previous year[10] - The total liabilities decreased to CNY 168,910,548.40 from CNY 199,805,604.96, showing a reduction of approximately 15.5%[19] - The company's retained earnings increased to CNY 317,880,160.74 from CNY 277,743,710.83, reflecting a growth of about 14.5%[19] Shareholder Information - Total number of common shareholders at the end of the reporting period is 15,695[12] - The largest shareholder, Linuo Investment Holding Group Co., Ltd., holds 31.12% of shares, amounting to 72,335,407 shares, with 57,000,000 shares pledged[12] - Jinan Financial Investment Fund holds 7.19% of shares, equivalent to 16,703,297 shares[12] - Jinan Hongdao New Energy Partnership holds 6.53% of shares, totaling 15,177,000 shares[12] - The top 10 shareholders account for a significant portion of the company's equity, with the largest holding being over 31%[12] - The company has a total of 4,469,230 restricted shares under the Minsheng Securities - CITIC Securities strategic placement plan[13] - The report indicates that there are no controlling relationships among the top 10 shareholders, ensuring independent decision-making[13] - The company has not disclosed any potential disputes or conflicts regarding shareholder equity[13] - The company is actively managing its shareholder structure to maintain stability and support growth initiatives[12] Inventory and Financing - Inventory increased by 49.68% to CNY 177,197,994.34 due to economic impacts[9] - The company reported a 306.86% increase in receivables financing to CNY 30,648,989.69, attributed to increased customer payments[9] - The company’s financial expenses decreased by 1165.43% to CNY -8,712,717.71, primarily due to exchange losses and interest expenses[10] Projects and Development - The company successfully launched the "Fully Electric Intelligent Pharmaceutical Glass Production Line Project" on July 15, 2022, which utilizes a new energy-efficient glass melting furnace[15] - The "Lightweight Thin-Walled High-End Pharmaceutical Glass Bottle Project" was successfully initiated on August 24, 2022, with an annual production capacity of over 5,000 tons of molded bottles, filling a gap in the company's product offerings[15] Research and Development - Research and development expenses amounted to CNY 17,703,334.37, a decrease of 27.1% from CNY 24,332,636.92 in Q3 2021[22]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥375,456,572.41, a decrease of 10.94% compared to ¥421,564,702.69 in the same period last year[23]. - Net profit attributable to shareholders was ¥61,739,044.45, showing a slight increase of 0.33% from ¥61,534,815.06 in the previous year[23]. - The net profit after deducting non-recurring gains and losses was ¥47,553,770.78, down 15.82% from ¥56,488,126.04 in the same period last year[23]. - The net cash flow from operating activities was -¥22,124,475.41, a significant decline of 194.04% compared to ¥23,526,990.81 in the previous year[23]. - Basic and diluted earnings per share were both ¥0.27, representing a decrease of 22.86% from ¥0.35 in the same period last year[23]. - The weighted average return on equity was 4.40%, down 6.17% from 10.57% in the previous year[23]. - The operating cost decreased by 9.45% to ¥284,573,160.86, resulting in a gross margin of 24.21%, down by 1.24% year-on-year[63]. - Research and development investment was ¥11,759,847.77, down 13.50% from the previous year[60]. - The company reported a total investment of ¥81,637,119.77 during the reporting period, an increase of 259.09% compared to ¥22,734,186.11 in the same period last year[72]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,570,072,063.03, an increase of 0.60% from ¥1,560,702,198.00 at the end of the previous year[23]. - Net assets attributable to shareholders increased by 1.13% to ¥1,376,226,196.80 from ¥1,360,896,593.04 at the end of the previous year[23]. - The company's long-term equity investments increased to ¥42,379,330.62, representing 2.70% of total assets[68]. - The company's fixed assets increased to ¥445,066,770.00, accounting for 28.35% of total assets, mainly due to investments in the expansion of the borosilicate glass production project[68]. - Total liabilities decreased to CNY 193,845,866.23 from CNY 199,805,604.96, a reduction of about 3.0%[170]. - Short-term borrowings were reduced to CNY 10,000,000.00 from CNY 25,000,000.00, a decrease of 60.0%[170]. Market and Product Development - Revenue from pharmaceutical glass reached 154.35 million yuan, representing a growth of 9.95% compared to the previous year[38]. - The company is focusing on expanding production capacity for neutral borosilicate pharmaceutical glass, with partial production lines becoming operational in May 2022[41]. - The company plans to launch new products, including a brown neutral borosilicate pharmaceutical glass tube project and a cartridge bottle project, expected to commence production in the second half of the year[42]. - The market for neutral borosilicate pharmaceutical glass in China is projected to grow significantly, with demand expected to rise from billions to hundreds of billions of units by 2026[32]. - The pharmaceutical glass market is expected to grow significantly due to increasing healthcare spending and an aging population, providing a favorable environment for the company's products[51]. Risk Management - The report highlights potential risks and the company's strategies to address them, which are detailed in the management discussion section[4]. - The company faces risks from intensified market competition, particularly in the pharmaceutical glass sector, with competitors expanding capacity[91]. - The company is exposed to risks from rising raw material and energy prices, which could impact gross margin if costs cannot be passed on[92]. - The ongoing COVID-19 pandemic continues to pose operational risks, with potential impacts on production if local outbreaks occur[98]. - The company aims to control costs and improve efficiency as a key focus for 2022 to mitigate potential gross margin declines[94]. Corporate Governance and Shareholder Relations - The company plans not to distribute cash dividends or issue bonus shares[4]. - The company held its first extraordinary general meeting of 2022 on April 8, with an investor participation rate of 52.52%[105]. - The annual general meeting for 2021 took place on May 10, 2022, with a participation rate of 58.02%[105]. - The company strictly adheres to legal regulations and maintains transparent communication with shareholders[115]. - There were no changes in the company's board of directors, supervisors, or senior management during the reporting period[106]. Environmental and Social Responsibility - The company was awarded the "Green Factory" honor by Shandong Province, reflecting its commitment to environmental protection and green production[43]. - The company has established a sound internal control system for environmental protection and energy consumption management[116]. - The company actively participates in public welfare activities, including donations during the pandemic[117]. Research and Development - The company has a robust R&D capability, holding over 80 patents, including more than 10 invention patents, and is recognized as a high-tech enterprise[54]. - The company has established a joint research institute with Qilu University of Technology to explore breakthroughs in special glass materials, including virtual reality glass substrates and optical glass[42]. - The company emphasizes the importance of retaining key technical personnel for product development and process improvement, implementing competitive incentive mechanisms to mitigate talent loss[99]. Shareholding Structure - The largest shareholder, Lino Investment Holding Group, holds 31.12% of shares, totaling 72,335,407 shares, with 12,222,223 shares frozen[152]. - The overall shareholding structure reflects a significant concentration of ownership among domestic investors, with 69.15% of shares held by domestic entities[146]. - The number of restricted shares decreased by 1,577,239, resulting in 184,114,368 restricted shares, which is 79.22% of total shares[146]. - The company has not undergone any changes in its controlling shareholder during the reporting period[157].

Financial Performance - The company's revenue for Q1 2022 was ¥188,550,996.54, a decrease of 4.06% compared to ¥196,529,204.68 in the same period last year[5] - Net profit attributable to shareholders increased by 28.20% to ¥31,307,449.92 from ¥24,420,400.93 year-on-year[5] - Total operating revenue for Q1 2022 was CNY 188,550,996.54, a decrease of 4.96% compared to CNY 196,529,204.68 in the same period last year[26] - Net profit for Q1 2022 reached CNY 31,307,449.92, representing an increase of 28.14% from CNY 24,420,400.93 in Q1 2021[27] - The total comprehensive income for the first quarter of 2022 was CNY 31,307,449.92, compared to CNY 24,420,400.93 in the same period last year, representing a year-over-year increase of approximately 28.5%[28] - Basic and diluted earnings per share for the first quarter were both CNY 0.13, slightly down from CNY 0.14 in the previous year[28] Cash Flow - The net cash flow from operating activities was negative at -¥21,106,625.27, a decline of 186.67% compared to ¥24,351,732.23 in Q1 2021[12] - Cash inflow from operating activities totaled CNY 174,840,478.54, an increase from CNY 169,518,396.72 in the prior year[31] - The company's cash flow from operating activities was impacted by increased payments for goods and services, totaling CNY 150,142,990.20, compared to CNY 97,872,953.94 in the previous year[31] - Cash outflow from investing activities was CNY 561,081,587.93, significantly higher than CNY 20,125,293.32 in the previous year, leading to a net cash flow from investing activities of negative CNY 341,559,691.09[32] - Cash flow from financing activities resulted in a net outflow of CNY 17,892,622.21, compared to a net outflow of CNY 5,333,537.88 in the same period last year[32] - The ending balance of cash and cash equivalents was CNY 322,059,409.47, down from CNY 41,866,392.01 at the end of the previous year[32] - The company's cash and cash equivalents decreased significantly by 34274.43% to -¥380,558,938.57 due to increased cash outflows from investment activities[13] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,547,107,757.79, down 0.87% from ¥1,560,702,198.00 at the end of the previous year[5] - Total liabilities decreased to CNY 154,903,714.83 from CNY 199,805,604.96, a reduction of 22.49%[24] - The company's equity attributable to shareholders increased to CNY 1,392,204,042.96 from CNY 1,360,896,593.04, an increase of 2.29%[24] Inventory and Receivables - Inventory increased by 46.50% to ¥173,430,662.92, primarily due to strategic procurement of pandemic-related materials[10] - Inventory increased to CNY 173,430,662.92, up 46.55% from CNY 118,384,314.87 at the beginning of the year[22] - The company reported a 98.32% increase in receivables financing to ¥14,939,705.95, attributed to increased customer acceptance payments[9] Shareholder Information - The total number of common shareholders at the end of the reporting period is 23,543[15] - Linuo Investment Holding Group Co., Ltd. holds 31.12% of the shares, amounting to 72,335,407 shares[16] - Jinan Hongdao New Energy Partnership holds 6.53% of the shares, totaling 15,177,000 shares[16] - The total number of restricted shares at the beginning of the period was 185,691,607, with 330,700 shares added during the period, resulting in a total of 186,022,307 restricted shares at the end of the period[19] - The total number of unrestricted shares held by the top ten shareholders includes 523,323 shares held by China Life Insurance Co., Ltd. - Traditional Products[16] - The total number of shares held by the top ten unrestricted shareholders is 2,500,000 shares[16] - The company plans to lift the restrictions on shares held by Linuo Investment Holding Group on November 11, 2024[18] Government Subsidies and R&D - The company received government subsidies amounting to ¥9,026,859.37, an increase of 337.86% compared to ¥2,061,589.24 in the same period last year[11] - Research and development expenses for Q1 2022 were CNY 5,996,354.46, slightly up from CNY 5,849,092.31 in Q1 2021[27] Other Information - The company has not reported any new product or technology developments in this quarter[19] - There are no mergers or acquisitions reported in the current financial period[19] - The company has not undergone an audit for the first quarter report[33] - The company approved the 2022 restricted stock incentive plan during the board meeting on March 23, 2022[20]

Financial Performance - The company's operating revenue for 2021 was ¥888,879,852.56, representing a 34.67% increase compared to ¥660,054,912.17 in 2020[22] - The net profit attributable to shareholders for 2021 was ¥124,780,673.54, a 37.42% increase from ¥90,803,000.02 in the previous year[22] - The net profit after deducting non-recurring gains and losses was ¥116,149,697.65, up 36.75% from ¥84,938,131.73 in 2020[22] - The basic earnings per share for 2021 was ¥0.70, a 34.62% increase compared to ¥0.52 in 2020[22] - The total assets at the end of 2021 reached ¥1,560,702,198.00, a 119.86% increase from ¥709,872,278.66 at the end of 2020[22] - The net assets attributable to shareholders increased by 146.76% to ¥1,360,896,593.04 from ¥551,496,131.93 in 2020[22] - The net cash flow from operating activities decreased by 40.85% to ¥52,467,645.38 from ¥88,704,124.54 in the previous year[22] - The weighted average return on equity for 2021 was 18.60%, slightly up from 17.93% in 2020[22] Revenue Breakdown - Sales of borosilicate pharmaceutical glass bottles reached approximately 220 million in 2021, marking a significant increase of 144.73% compared to the previous year[31] - The revenue from heat-resistant glass products was approximately 516 million in 2021, reflecting a growth of 23.20% year-on-year[32] - The company’s revenue from pharmaceutical glass reached approximately 308 million in 2021, a year-on-year increase of 78.90%, significantly outpacing industry growth[35] - The proportion of pharmaceutical glass revenue in total revenue rose from 26.08% to 34.65%, highlighting its importance as a growth driver[47] - The production of heat-resistant glass generated revenue of ¥515,787,857.66, accounting for 58.03% of total revenue, with a year-on-year growth of 23.20%[71] Market Position and Strategy - The company has established itself as a core supplier for major pharmaceutical companies, including Shanghai Pharmaceuticals and Yangtze River Pharmaceutical Group[36] - The pharmaceutical glass market in China is projected to grow at a compound annual growth rate of 9%, reaching over 40 billion by 2025[35] - The company is positioned as a leading player in the high borosilicate glass market, with strong brand advantages and extensive customer collaborations[42] - The company is focusing on expanding its production capacity for neutral borosilicate medicinal glass and high borosilicate glass products to capture market opportunities in the healthcare sector[50] - The company plans to strengthen strategic cooperation with major clients to increase market share and expand into international markets[107] Research and Development - The company invested 32.50 million yuan in R&D, a 33.96% increase compared to the previous year, and obtained 9 new patents during the reporting period[48] - The company emphasizes research and innovation to enhance production efficiency and reduce costs in the pharmaceutical packaging and heat-resistant glass sectors[47] - The company is focusing on expanding its product range and enhancing product quality through advanced technologies, such as the development of a surface coating technique for medicinal glass tubes[82] - The company is committed to strengthening R&D investment in the special glass field, focusing on high value-added products and new application areas to enhance core competitiveness[109] Governance and Compliance - The company has established a governance structure that complies with relevant laws and regulations, ensuring the accuracy and integrity of financial reporting[53] - The company maintains a robust governance structure, with independent operations from its controlling shareholder, ensuring no adverse effects on governance or independence during the reporting period[129] - The company has established an independent financial accounting department and a complete financial management system, ensuring financial independence and compliance with tax obligations[137] - The company has implemented a comprehensive internal control system to effectively prevent operational risks and ensure compliance with regulations[187] Employee and Training Initiatives - A total of 3,717 employees received training, with an average training duration of 30.71 hours per employee, totaling an investment of 1.51 million yuan in training[52] - The company has established a training plan to enhance employee skills and has focused on high-skill talent development[182] - The total number of employees at the end of the reporting period was 1,124, with 851 in production, 126 in technical roles, and 56 in sales[179] Environmental and Social Responsibility - The company was recognized as a "Green Factory" in Jinan City in 2021, reflecting its commitment to environmental protection and energy efficiency[195] - The company has implemented measures to enhance its environmental protection facilities, ensuring compliance with national environmental regulations[194] - The company reported that all pollutants generated during production met national discharge standards[194] - The company actively fulfills its corporate social responsibility, maintaining communication with stakeholders to balance interests among shareholders, employees, and society[130] Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25% based on new product launches and market expansion strategies[157] - The company plans to invest 200 million RMB in R&D for innovative technologies over the next three years[157] - The company aims to improve compliance governance by enhancing internal control systems and conducting targeted compliance training for management and employees[110] - The company plans to control costs and improve efficiency as a key focus for 2022, aiming to stabilize gross profit margins despite potential fluctuations[114]